NervGen Q2 Loss Widens on Warrant Charge; Phase 3 RESTORE Screening Set for September
NGEN sits 16% above its 52-week low of $1.58.
Summary
NervGen reported Q2 2026 results with a C$29.2M net loss, largely from a non-cash warrant derivative charge, and confirmed Phase 3 RESTORE screening begins September 2026 with cash runway through 1H 2028.
Key Events · Earnings and Guidance · NGEN
-
Q2 Net Loss Driven by Non-Cash Warrant Charge
Net loss was C$29.2M for Q2 2026, including a C$19.4M non-cash unrealized loss on warrant derivatives. The warrant derivative is remeasured each period and does not reflect operating performance or cash requirements.
-
Cash Runway Through 1H 2028
Cash and cash equivalents totaled C$86.8M (US$61.1M) as of June 30, 2026, which management expects to fund operations through the anticipated topline data readout from the Phase 3 RESTORE study in 1H 2028.
-
Phase 3 RESTORE Screening Begins September 2026
Site activation and screening for the Phase 3 RESTORE study of NVG-291 in chronic spinal cord injury is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.
-
New ATM Program Established, No Shares Sold
On July 2, 2026, the company established a new at-the-market equity program for up to US$50 million in common shares. Through the date of the release, no common shares have been sold under the ATM program.
Analysis · NGEN · Life Sciences
NervGen reported a C$29.2M net loss for Q2 2026, driven largely by a C$19.4M non-cash warrant derivative remeasurement loss. The company holds C$86.8M in cash, which management says funds operations through the anticipated RESTORE topline readout in 1H 2028. Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant dosed shortly thereafter. The warrant derivative loss is a non-cash mark-to-market change driven by the share price, not a cash outflow or new dilution.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.5% of the 1629 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NGEN was trading at $1.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $144.7M. The 52-week trading range was $1.58 to $6.30. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.